Martin Gleave

Researcher
  • University of British Columbia
  • Vancouver Prostate Centre
Home > About Us > Our People > Researcher Bio
  • Bio

Related Research

  • Prostate Cancer

    Targeting Tumour Plasticity in Advanced Prostate Cancer

    Nearly 20% of advanced prostate cancer patients relapse on potent androgen receptor (AR) targeted therapies with a highly aggressive disease called treatment induced neuroendocrine prostate cancer (NE...

    Read More
  • Completed
    Prostate Cancer

    Targeting the adaptive molecular landscape in castrate-resistant prostate cancer

    TFRI’s Vancouver-based prostate cancer progression team is primed and ready to continue its world-class research on advanced, drug-resistant tumours after receiving a five-year renewal of Terry ...

    Read More
  • Completed
    Prostate Cancer

    A pan-Canadian initiative for the development of a biomarker-driven approach to the management of prostate cancer

    A collection of more than 2,000 tumour samples. Over a dozen Canadian researchers. Four provinces. These are just some of the numbers behind TFRI’s Canadian Prostate Cancer Biomarker Network (CP...

    Read More
  • Completed
    Prostate Cancer

    Prostate cancer progression

    Significant progress has been made in treating prostate cancer, but survival rates remain low for the most advanced, drug-resistant forms of the disease – a reality the TFRI’s prostate can...

    Read More

Related News & Events

  • Press Release|May 27, 2020

    Clinical trial reveals more effective way to treat aggressive prostate cancers

    A clinical trial led by BC-based researchers partly funded by the TFRI has revealed that administering abiraterone acetate first, with enzalutamide af...

  • Research Highlight|October 16, 2019

    New finding sheds light on neuroendocrine prostate cancer progression

    New study reveals how RNA splicing of BHC80 promotes the development of treatment-induced neuroendocrine prostate cancer, providing potential avenue f...

  • Research Highlight|June 03, 2019

    New research suggests immunotherapy could help nearly 50 per cent of patients with rare mesothelioma

    A team of scientists partly funded by the Terry Fox Research Institute has shown that nearly half of all patients with peritoneal mesothelioma (PeM), ...

  • Research Highlight|May 15, 2018

    Breakthrough test uses ctDNA to determine treatment resistance in advanced prostate cancer patients

    Metastatic castration-resistant prostate cancer (mCRPC) patients are now one step closer to more personalized treatment, thanks to a new test that can...

  • Research Highlight|January 03, 2017

    Clusterin knockdown sensitizes prostate cancer cells to therapies by modulating mitosis

    A study by a TFRI-funded team based at the Vancouver Prostate Centre has found that silencing a key driver of castrate-resistant prostate cancer and r...

  • Press Release|September 07, 2016

    TFRI ANNOUNCES 2016 FUNDING COMPETITION AWARD RECIPIENTS

    Vancouver, BC – Six outstanding Canadian research teams will use $27.3 million in new funding to engineer precision medicines for patients whose cance...

  • TFRI News|July 25, 2012

    New pan-Canadian Terry Fox Research Institute network receives close to $4-million to find better tools to treat prostate cancer

    New pan-Canadian Terry Fox Research Institute network receives close to $4-million to find better tools to treat prostate cancer

  • All News & Events